Jan 15, 2019
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
Jan 07, 2019
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
Nov 09, 2018
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
Nov 09, 2018
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
Nov 05, 2018
Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
Oct 22, 2018
Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial
Oct 21, 2018
Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
Oct 15, 2018
Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
Jun 07, 2018
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
May 31, 2018
Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting
Apr 24, 2018
Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials
Mar 08, 2018
Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results
Nov 16, 2017
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
Sep 14, 2017
Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer
Sep 06, 2017
Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer
Aug 03, 2017
Mirati Therapeutics Reports Second Quarter 2017 Financial Results